-

Medable to Present at Jefferies Global Healthcare Conference

PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., the leading evidence-generation platform provider for modern clinical trials, today announced that Medable Co-founder and CEO Michelle Longmire will present at the Jefferies Global Healthcare Conference. The live presentation will take place on Thursday, June 6, 2024, at 3:30p.m. ET in New York City, New York.

The Management Team will also be available for 1:1 investor meetings at the conference. Please reach out to your Jefferies representative to schedule.

For more information, please contact:
Burak Over
SVP, Corporate Development & Investor Relations
burak@medable.com

To learn more about Medable, visit medable.com.

About Medable

Medable is on a mission to get effective therapies to people faster. Its digital clinical trials platform enhances speed, scale, and patient access in clinical research, accelerating medicines for thousands of conditions without treatment or cure. Named a Leader in the industry by Everest Group and awarded Best Digital Health Solution by the Galien Foundation, the Medable platform has been deployed in more than 300 trials in 60 countries and 120 languages, serving more than one million patients globally. Medable is a privately held, venture-backed company headquartered in Palo Alto, California, and ranked #398 on the Inc. 5000 in 2023.

Contacts

Lisa Barbadora, Barbadora INK for Medable
+1 (610) 420-3413
lbarbadora@barbadoraink.com / media@medable.com

Industry:

Medable Inc.

Details
Headquarters: Palo Alto, California
CEO: Michelle Longmire
Employees: 350
Organization: PRI
Release Versions
English

Contacts

Lisa Barbadora, Barbadora INK for Medable
+1 (610) 420-3413
lbarbadora@barbadoraink.com / media@medable.com

Social Media Profiles
Medable on LinkedIn
More News From Medable Inc.

Medable Launches Partner Program for Faster Clinical Trial Startup, Greater Control, and Transparent Pricing

PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., a leading provider of clinical development technology, today unveiled its new Partner Program, designed to empower contract research organizations (CROs) and other partners with generative AI-driven, self-service eCOA build capabilities for digitally enabled clinical trials. Leveraging the Medable platform, the program eliminates traditional bottlenecks for CROs to accelerate timelines by 50% or more, while delivering administrative and financia...

Medable Introduces Long-Term Follow-Up Model for Cell & Gene Therapy (CGT) Trials to Reduce Costs and Improve Patient Access

PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., a leading technology platform provider for decentralized clinical trials, today unveiled its digital-first Long-Term Follow-Up (LTFU) model for cell and gene therapy (CGT) trials. Medable’s platform reduces the burden on patients and sites involved in complex CGT trials and enhances scientific integrity with sustainable data capture across the FDA-required 15-year follow-up period for certain CGTs, including those using genome-editing techniques...

Medable Releases New Digital Oncology Trial Offering to Reduce Complexity for Sites, Sponsors, Patients, and Caregivers

PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., a leading provider of clinical development and eCOA technology, today announced its next-generation digital oncology trial offering specifically designed to reduce operational complexity for sites and sponsors while meeting vulnerable cancer patients and their caregivers where they are with accessible, digital tools. Oncology trials have historically been complicated but are becoming increasingly complex due to factors like advanced precision me...
Back to Newsroom